%0 Journal Article %A Spanakis Nikolaos %A Kassela Katerina %A Dovrolis Nikolas %A Bampali Maria %A Gatzidou Elisavet %A Kafasi Athanasia %A Froukala Elisavet %A Stavropoulou Anastasia %A Lilakos Konstantinos %A Veletza Stavroula %A Tsiodras Sotirios %A Tsakris Athanasios %A Karakasiliotis Ioannis %T Dominant and rare SARS-Cov2 variants responsible for the COVID-19 pandemic in Athens, Greece %D 2020 %R 10.1101/2020.06.03.20121236 %J medRxiv %P 2020.06.03.20121236 %X SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel Coronavirus responsible for the Coronavirus Disease-2019 (COVID-19) pandemic. Since the beginning of the pandemic, the virus has spread in almost the entire world. Tracing and tracking virus international and local transmission has been an enormous challenge. Chains of infections starting from various countries worldwide seeded the outbreak of COVID-19 in Athens, capital city of Greece. Full-genome analysis of isolates from Athens’ Hospitals and other healthcare providers revealed the variety of SARS-CoV-2 that initiated the pandemic before lock-down and passenger flight restrictions. The present work may serve as reference for resolving future lines of infection in the area and Europe especially after resumption of passenger flight connections to Athens and Greece during summer of 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCo‐financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH/CREATE/INNOVATE (project code:T1EDK/5000)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee, National and Kapodistrian University of AthensAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available is NCBI and GISAID platforms as indicated in the manuscript https://www.gisaid.org/ https://www.ncbi.nlm.nih.gov/nucleotide/ %U https://www.medrxiv.org/content/medrxiv/early/2020/06/05/2020.06.03.20121236.full.pdf